CARIS LIFE SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CARIS LIFE SCIENCES, INC. (CAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $1.60M, a 85.19% decline year-over-year.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.40M, a 22.22% decline year-over-year.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $7.70M, a 3750.00% increase year-over-year.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $8.70M, a 690.91% increase year-over-year.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $21.20M, a 657.14% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.80M, a 58.82% decline from fiscal 2023.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $6.80M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-05 | $3.10M 10-Q · filed 2026-08-05 | $10.70M derived: sum of 3 quarters · filed 2026-08-05 | $19.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-08 | $9.10M derived: sum of 2 quarters · filed 2026-05-08 | $17.80M derived: sum of 3 quarters · filed 2026-05-08 | $28.60M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $16.40M derived: sum of 2 quarters · filed 2026-03-03 | $27.20M derived: sum of 3 quarters · filed 2026-08-05 | $21.20M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $8.70M 10-Q · filed 2025-11-05 | $19.50M derived: sum of 2 quarters · filed 2026-08-05 | $13.50M 10-Q · filed 2025-11-05 | $21.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $10.80M 10-Q · filed 2026-08-05 | $12.60M 10-Q · filed 2026-08-05 | $12.61M 10-Q · filed 2025-08-12 | $12.80M derived: sum of 3 quarters · filed 2026-08-05 | $13.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.80M 10-Q · filed 2026-05-08 | $2.00M derived: sum of 2 quarters · filed 2026-05-08 | $3.10M derived: sum of 3 quarters · filed 2026-05-08 | $4.20M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.30M derived: sum of 2 quarters · filed 2026-03-03 | $2.40M derived: sum of 3 quarters · filed 2026-03-03 | $2.80M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $1.10M 10-Q · filed 2025-11-05 | $2.20M derived: sum of 2 quarters · filed 2025-11-05 | $2.60M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $1.10M 10-Q · filed 2025-08-12 | $1.50M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $6.80M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |